Phibro Animal Health (NASDAQ:PAHC) Raised to “Hold” at Citigroup

Phibro Animal Health (NASDAQ:PAHC) was upgraded by research analysts at Citigroup to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Several other equities analysts also recently issued reports on PAHC. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a research report on Friday, February 6th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $42.40.

Phibro Animal Health Price Performance

NASDAQ PAHC opened at $55.71 on Wednesday. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The stock’s fifty day moving average price is $53.29 and its 200 day moving average price is $44.96. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $60.08. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 24.76, a PEG ratio of 0.84 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The firm had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities research analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current year.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $54.64, for a total transaction of $384,665.60. Following the sale, the chief executive officer directly owned 117,000 shares of the company’s stock, valued at approximately $6,392,880. This trade represents a 5.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 316,205 shares of company stock worth $15,487,684. 50.13% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Phibro Animal Health by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after acquiring an additional 13,884 shares in the last quarter. State Street Corp boosted its stake in shares of Phibro Animal Health by 5.4% during the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock worth $35,204,000 after acquiring an additional 48,243 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after acquiring an additional 626,492 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after acquiring an additional 21,951 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Phibro Animal Health by 1.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock worth $18,394,000 after acquiring an additional 6,826 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.